Topics
• Prevalence in PD vs HD
–Predictors in PD and HD
• Impact of anemia on survival in PD and HD patients
• Iron markers in PD and HD
• ESAs use in PD
–Prevalence
–Efficacy
–ESAs hyporesponsiveness in PD (and HD)
CONCLUSIONS
• PD patients more frequently experienced Hb levels>10g/dl than HD patients (fig.1)
• The relationship between mortality and levels of HB and ESA dose and mortality is much less strict in PD than in HD (fig.1-2)
• The iron therapy is practiced in a minority of patients (fig.2)
• Ferritin levels are much lower than in HD patients (inflammation?) with comparable levels of TSAT (fig.3)
• The patterns of iron treatment used in HD cannot necessarily be the same in PD (fig.4)
• The percentage of patients receiving ESAs is significantly lower in PD than in HD. Both in PD and HD, this percentage is increasing over time (fig.5)
• The sensitivity to ESAs is about 40% higher in PD compared to HD and predictors of responsiveness are not always the same in the two groups (fig.5-6)